Neo Ivy Capital Management Nektar Therapeutics Transaction History

Neo Ivy Capital Management

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$3.17 - $6.17 $12,927 - $25,161	-4,078 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $14,302 - $47,169	3,438 Added 537.19%	4,078 $22,000
Q4 2021 Feb 15, 2022	SELL	$10.83 - $18.41 $4,082 - $6,940	-377 Reduced 37.07%	640 $8,000
Q3 2021 Nov 16, 2021	BUY	$13.07 - $18.84 $13,292 - $19,160	1,017 New	1,017 $24,000
Q1 2021 Oct 07, 2021	SELL	$16.56 - $25.46 $76,821 - $118,108	-4,639 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $73,157 - $88,280	4,639 New	4,639 $79,000
Q2 2020 Aug 17, 2020	SELL	$16.86 - $23.44 $17,146 - $23,838	-1,017 Closed	0 $0
Q2 2020 Aug 17, 2020	SELL	$16.86 - $23.44 $22,592 - $31,409	-1,340 Reduced 56.85%	1,017 $24,000
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $34,105 - $65,901	2,357 New	2,357 $42,000
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $603,588 - $885,887	-19,113 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $581,608 - $1.08 Million	19,113 New	19,113 $628,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.